NCT00572572 - Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

February 28, 2011

Conditions

Germ Cell Tumors

Interventions

DRUG

Aprepitant

Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.

DRUG

Placebo

Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.

Trial Locations (6)

University of Pennsylvania, Philadelphia

Indiana University Simon Cancer Center, Indianapolis

Medical Consultants, P.C., Muncie

Froedtert/Medical College of Wisconsin, Milwaukee

Siteman Cancer Center, St Louis

Providence Portland Medical Center, Portland